Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
about
Drug treatment of inborn errors of metabolism: a systematic reviewStructure-based design and mechanisms of allosteric inhibitors for mitochondrial branched-chain α-ketoacid dehydrogenase kinase.Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients.Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate.Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetateUrinary Metabolic Phenotyping Reveals Differences in the Metabolic Status of Healthy and Inflammatory Bowel Disease (IBD) Children in Relation to Growth and Disease Activity.Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disordersAn update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.
P2860
Q26864796-DB53418A-BC2B-4970-BF08-C5A200E44D4DQ28291558-0E91DFAB-F811-44AE-9C13-62480C4F0BA1Q33687277-6CCE9A40-93EC-4E82-9FA2-5E38FCE7C108Q33800136-60BE24AF-4912-4014-9B87-42A68F6F631DQ36001522-779C476A-D4E8-4741-B9B1-E6EE92E2B290Q37210128-18A4B844-3E09-4E62-BA33-FADBA7134EA6Q37582146-D70052A1-6DDB-4E15-82FE-2B211665A87AQ39012545-2F2C8F4E-847A-4F24-A40D-93BD955DBD04
P2860
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
@ast
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
@en
type
label
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
@ast
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
@en
prefLabel
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
@ast
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
@en
P2093
P2860
P50
P1476
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders
@en
P2093
A Feigenbaum
B F Scharschmidt
C O Harding
D Bartholomew
D F Coakley
P2860
P304
P356
10.1016/J.YMGME.2012.08.006
P577
2012-08-18T00:00:00Z